1067 related articles for article (PubMed ID: 26205340)
1. Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Melero I; Berman DM; Aznar MA; Korman AJ; Pérez Gracia JL; Haanen J
Nat Rev Cancer; 2015 Aug; 15(8):457-72. PubMed ID: 26205340
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control.
Schoenhals JE; Seyedin SN; Tang C; Cortez MA; Niknam S; Tsouko E; Chang JY; Hahn SM; Welsh JW
Cancer J; 2016; 22(2):130-7. PubMed ID: 27111909
[TBL] [Abstract][Full Text] [Related]
3. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
4. Emerging Opportunities and Challenges in Cancer Immunotherapy.
Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
6. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
7. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Patel SA; Minn AJ
Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial Cancer Immunotherapies.
Hellmann MD; Friedman CF; Wolchok JD
Adv Immunol; 2016; 130():251-77. PubMed ID: 26923003
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
10. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Robert L; Ribas A; Hu-Lieskovan S
Semin Immunol; 2016 Feb; 28(1):73-80. PubMed ID: 26861544
[TBL] [Abstract][Full Text] [Related]
11. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy: the beginning of the end of cancer?
Farkona S; Diamandis EP; Blasutig IM
BMC Med; 2016 May; 14():73. PubMed ID: 27151159
[TBL] [Abstract][Full Text] [Related]
13. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Havel JJ; Chowell D; Chan TA
Nat Rev Cancer; 2019 Mar; 19(3):133-150. PubMed ID: 30755690
[TBL] [Abstract][Full Text] [Related]
14. Current status and future prospects of the strategy of combining CAR‑T with PD‑1 blockade for antitumor therapy (Review).
Xu J; Zhang Q; Tian K; Wang H; Yin H; Zheng J
Mol Med Rep; 2018 Feb; 17(2):2083-2088. PubMed ID: 29207115
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Kyi C; Postow MA
Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy a New Hope for Cancer Treatment: A Review.
Nouri Rouzbahani F; Shirkhoda M; Memari F; Dana H; Mahmoodi Chalbatani G; Mahmoodzadeh H; Samarghandi N; Gharagozlou E; Mohammadi Hadloo MH; Maleki AR; Sadeghian E; Nia E; Nia N; Hadjilooei F; Rezaeian O; Meghdadi S; Miri S; Jafari F; Rayzan E; Marmari V
Pak J Biol Sci; 2018; 21(3):135-150. PubMed ID: 30187723
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
Hughes PE; Caenepeel S; Wu LC
Trends Immunol; 2016 Jul; 37(7):462-476. PubMed ID: 27216414
[TBL] [Abstract][Full Text] [Related]
18. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
19. Harnessing tumor-associated macrophages as aids for cancer immunotherapy.
Li X; Liu R; Su X; Pan Y; Han X; Shao C; Shi Y
Mol Cancer; 2019 Dec; 18(1):177. PubMed ID: 31805946
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
Emens LA; Ascierto PA; Darcy PK; Demaria S; Eggermont AMM; Redmond WL; Seliger B; Marincola FM
Eur J Cancer; 2017 Aug; 81():116-129. PubMed ID: 28623775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
